Malignancies and soluble tumor antigens in rheumatic diseases

被引:65
作者
Szekanecz, Eva
Andras, Csilla
Sandor, Zsuzsa
Antal-Szalmas, Peter
Szanto, Janos
Tamasi, Laszlo
Kiss, Emese
Szekanecz, Zoltan
机构
[1] Univ Debrecen, Dept Internal Med 3, Med & Hlth Sci Ctr, Div Rheumatol, H-4004 Debrecen, Hungary
[2] Univ Debrecen, Dept Oncol, Med & Hlth Sci Ctr, H-4004 Debrecen, Hungary
[3] Univ Debrecen, Dept Pathol, Med & Hlth Sci Ctr, H-4004 Debrecen, Hungary
[4] Univ Debrecen, Dept Internal Med 3, Med & Hlth Sci Ctr, Div Clin Immunol, H-4004 Debrecen, Hungary
[5] Univ Debrecen, Dept Clin Biochem & Mol Pathol, Med & Hlth Sci Ctr, H-4004 Debrecen, Hungary
[6] St Francis Hosp, Dept Rheumatol, Miskolc, Hungary
关键词
paraneoplasia; rheumatic syndromes; tumor-associated antigens;
D O I
10.1016/j.autrev.2006.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drags used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anfi-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:42 / 47
页数:6
相关论文
共 36 条
[1]   CANCER IN SYSTEMIC-SCLEROSIS [J].
ABUSHAKRA, M ;
GUILLEMIN, F ;
LEE, P .
ARTHRITIS AND RHEUMATISM, 1993, 36 (04) :460-464
[2]  
AIRIO A, 1995, J RHEUMATOL, V22, P1300
[3]  
Asten P, 1999, J RHEUMATOL, V26, P1705
[4]   The incidence of cancer associated with the treatment of rheumatoid arthritis [J].
Beauparlant, P ;
Papp, K ;
Haraoui, B .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1999, 29 (03) :148-158
[5]   Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].
Brown, SL ;
Greene, MH ;
Gershon, SK ;
Edwards, ET ;
Braun, MM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158
[6]  
CALLEN JP, 1994, RHEUM DIS CLIN N AM, V20, P943
[7]   Rheumatic syndromes associated with malignancy [J].
Chakravarty, E ;
Genovese, MC .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (01) :35-43
[8]  
ENOMOTO M, 2000, INTERNAL MED, V39, P9
[9]   A NOVEL ANTINUCLEAR ANTIBODY ASSOCIATED WITH A LUPUS-LIKE PARA-NEOPLASTIC SYNDROME [J].
FREUNDLICH, B ;
MAKOVER, D ;
MAUL, GG .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (04) :295-297
[10]   Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas [J].
Geborek, P ;
Bladström, A ;
Turesson, C ;
Gulfe, A ;
Petersson, IF ;
Saxne, T ;
Olsson, H ;
Jacobsson, LTH .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) :699-703